This topic contains a solution. Click here to go to the answer

Author Question: The major non-glucose-reducing substance present in serum is: A) Urea B) Protein C) Ascorbic ... (Read 329 times)

Marty

  • Hero Member
  • *****
  • Posts: 553
The major non-glucose-reducing substance present in serum is:
 
  A) Urea
  B) Protein
  C) Ascorbic acid
  D) Glutathione
  E) Cholesterol

Question 2

During 3 glucose tests an hour apart on a patient, capillary blood is substituted for venous blood for one of the timed samples. What results would you expect for the sample, as compared to results expected for venous blood drawn at the same time?
 
  A) Capillary blood will yield higher results than venous blood
  B) Venous blood will yield higher results than capillary blood
  C) Results from capillary and venous blood will be substantially the same



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by a Subject Expert

vboyd24

  • Sr. Member
  • ****
  • Posts: 341
Answer to Question 1

Ans: C

Answer to Question 2

Ans: A




Marty

  • Member
  • Posts: 553
Reply 2 on: Aug 10, 2018
Great answer, keep it coming :)


JCABRERA33

  • Member
  • Posts: 344
Reply 3 on: Yesterday
:D TYSM

 

Did you know?

Cutaneous mucormycosis is a rare fungal infection that has been fatal in at least 29% of cases, and in as many as 83% of cases, depending on the patient's health prior to infection. It has occurred often after natural disasters such as tornados, and early treatment is essential.

Did you know?

Patients who cannot swallow may receive nutrition via a parenteral route—usually, a catheter is inserted through the chest into a large vein going into the heart.

Did you know?

Drug-induced pharmacodynamic effects manifested in older adults include drug-induced renal toxicity, which can be a major factor when these adults are experiencing other kidney problems.

Did you know?

Though Candida and Aspergillus species are the most common fungal pathogens causing invasive fungal disease in the immunocompromised, infections due to previously uncommon hyaline and dematiaceous filamentous fungi are occurring more often today. Rare fungal infections, once accurately diagnosed, may require surgical debridement, immunotherapy, and newer antifungals used singly or in combination with older antifungals, on a case-by-case basis.

Did you know?

Bisphosphonates were first developed in the nineteenth century. They were first investigated for use in disorders of bone metabolism in the 1960s. They are now used clinically for the treatment of osteoporosis, Paget's disease, bone metastasis, multiple myeloma, and other conditions that feature bone fragility.

For a complete list of videos, visit our video library